Neoadjuvant Chemoimmunotherapy for Resectable NSCLC
Karen M. Yun, MD, discusses the role for neoadjuvant chemoimmunotherapy in patients with resectable non–small cell lung cancer.
Video Player is loading.
EP: 1.Introduction of the UCSD vs City of Hope Face-Off
EP: 2.Advanced ALK-Rearranged NSCLC
EP: 3.Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN
EP: 4.CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC
EP: 5.Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?
EP: 6.A Case of Metastatic ROS1 Fusion-Positive NSCLC
EP: 7.Patient Profile: EGFRm Post-Osimertinib
EP: 8.Patient Case: PD-L1 Negative NSCLC
EP: 9.KRAS Patient Case
Now Viewing
EP: 10.Neoadjuvant Chemoimmunotherapy for Resectable NSCLC
EP: 11.Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?
EP: 12.Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy
EP: 13.Treatment Options for Patients with EGFRm: EGFR TKI
EP: 14.Face-Off: Award Ceremony
Recent Videos
Clinical Scenario: TP53- Mutant AML
Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation
Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care
Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing
AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center
Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma
Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy
Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma
Related Content
